(R)-69
Chemical compound
From Wikipedia, the free encyclopedia
(R)-69 (3IQ) is a drug of the tetrahydropyridinylpyrrolopyridine family related to the psychedelic tryptamines which acts as a 5-HT2A receptor agonist, with 4.6-fold selectivity over 5-HT2B and 49-fold selectivity over 5-HT2C.[1][2] It has a 5-HT2A Ki of 680 nM and an EC50 of 41 nM.[1][2] (R)-69 is a biased agonist selective for activation of the Gq coupled signalling pathway, with much weaker activation of the β-arrestin 2 coupled pathway.[1][2][3] In animal studies it produces antidepressant-like activity but without producing the head-twitch response associated with psychedelic effects.[1][2] The drug was identified along with its close analogue (R)-70 via an ultra-large-scale docking campaign against the serotonin 5-HT2A receptor and was first described by Bryan L. Roth and colleagues in 2022.[1][2] A number of related derivatives have also been developed.[4][5]
-69.svg) | |
| Clinical data | |
|---|---|
| Other names | R-69; 3IQ |
| Drug class | Non-hallucinogenic Serotonin 5-HT2A receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H15N3 |
| Molar mass | 213.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
